Immuno-oncology co-culture models market seen topping $1.7 billion by 2030
The global immuno-oncology co-culture models market is projected to grow from $1.06 billion in 2026 to $1.76 billion by 2030, driven by demand for more predictive cancer research tools. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.
Why it matters: - Immuno-oncology co-culture models are becoming a key tool for studying how cancer and immune cells interact. - The market’s growth reflects rising demand for more predictive preclinical testing and more personalized cancer research. - Faster adoption of these models could help drug developers improve immunotherapy screening and targeted treatment development.
What happened: - The Business Research Company released its Immuno-Oncology Co-Culture Models Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report says the global market will rise from $0.93 billion in 2025 to $1.06 billion in 2026. - The report projects the market will reach $1.76 billion by 2030.
The details: - The report puts 2026-2030 compound annual growth at 13.6%. - The market’s recent growth is tied to increased funding for cancer research, wider use of in vitro disease models and growing interest in immunotherapy development. - The report also cites rising demand for predictive preclinical testing and more advanced cell culture technologies. - Looking ahead, the report points to stronger demand for personalized immuno-oncology studies, patient-derived tumor models and next-generation preclinical platforms. - The report highlights growing use of organoid and microfluidic technologies. - Other trends include three-dimensional tumor microenvironment models, patient-derived co-culture systems, predictive immunotherapy screening tools and deeper tumor-immune interaction studies. - Immuno-oncology co-culture models combine immune cells and tumor cells in vitro to mimic the tumor-immune microenvironment. - These systems help researchers observe cancer-immune interactions under controlled conditions. - The models offer a more realistic setting than traditional monoculture methods for assessing immune responses, tumor behavior and immunotherapeutic performance. - The report says the market is also being pushed by the rising global cancer burden. - In October 2025, Australian Government data showed about 169,759 new cancer diagnoses and roughly 53,545 cancer-related deaths. - The report says North America held the leading market position in 2025. - Asia-Pacific is expected to grow faster than other regions in the coming years. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.
Between the lines: - The forecast suggests cancer research is moving toward models that better reflect human biology, not just faster lab workflows. - That shift favors platforms that can improve confidence in preclinical results before drugs move into costly late-stage testing. - The regional outlook points to broadening adoption beyond the current North American lead.
What's next: - The report says future market growth will depend on broader use of patient-derived models, organoids and microfluidic systems. - The Business Research Company also added new report tools for 2026, including market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards and market hotspot infographics. - More information is available in the full report and a free sample.
The bottom line: - Immuno-oncology co-culture models are moving from niche lab tools to a fast-growing market tied to the push for better cancer drugs and more precise preclinical research.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
The Governance Reporter of Australia
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.